Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN SODIUM versus CLOXAPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN SODIUM versus CLOXAPEN.
AMPICILLIN SODIUM vs CLOXAPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
1-2 g IV/IM every 4-6 hours for serious infections; maximum 12 g/day.
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life ~1 hour in healthy adults; prolonged to 2–5 hours in renal impairment (CrCl <10 mL/min) and up to 7–20 hours in anuria; neonatal half-life 2–4 hours.
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
Approximately 90% renal excretion via tubular secretion and glomerular filtration; small biliary excretion (<10%); fecal elimination negligible.
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic